Monday, November 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· March 31, 2026

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights

View original at finance.yahoo.com
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights Aptose Biosciences, Inc…
Opening lines of the source · Yahoo Finance · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Shareholders have approved the proposed arrangement with Hanmi, which enables continued and expanded development of the TUS+VEN+AZA triplet

    60% confidence
  • The clinical trial data continue to support the promise of TUS+VEN+AZA therapy

    60% confidence
  • TUS+VEN+AZA triplet has shown promising response rates and safety as a mutation agnostic therapy across a diverse population of patients newly diagnosed with AML

    60% confidence
  • TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations

    60% confidence

Cited in these Via News reports